Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To systematically assess the effects of neoadjuvant chemotherapy on the prognostic risk of invasive transitional bladder cancer.
Methods: All known randomized controlled trials (RCTs) on neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer, published from the date of database building to September 2012, were retrieved from such databanks as Pubmed, CBMdisc, Embase and Cochrane. The data on 5-year survival rate of included studies were extracted for further heterogeneity exploration, subgroup analysis and statistical pooling with the RevMan 5.10 software.
Results: Fourteen subjects involving 2072 cases and 2086 controls were published from 1991 to 2012. The overall odds ratio of survival suggested a 21% relative reduction in mortality risk for neoadjuvant chemotherapy compared to that on control (OR = 0.79, 95%CI:0.70-0.90). In subgroup analysis according to different neoadjuvant chemotherapies, MCV (methotrexate, cisplatin and vinblastine) and MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapies showed significant benefit to overall survival with 28% and 25% reduction in risk of death respectively (OR = 0.72,95%CI:0.60-0.86, OR = 0.75,95%CI:0.59-0.96) . However, no significant difference existed in effects between C (cisplatin) chemotherapy, CM (cisplatin and methotrexate) chemotherapy and CD (cisplatin and docetaxel) chemotherapy and controls. In subgroup analysis according to local treatment of cystectomy or radiotherapy after neoadjuvant chemotherapy, the patients with cystectomy showed significant benefits in overall survival with 25% reduction in risk of death (OR = 0.75, 95%CI:0.65-0.87). However, the patients with radiotherapy or radiotherapy plus cystectomy showed no significant benefits in overall survival.
Conclusions: MCV and MVAC neoadjuvant chemotherapies improve survival among patients with bladder cancer. And neoadjuvant chemotherapy has better long-term survival after cystectomy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
Cancer
September 2025
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.
Background: Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off-trial patients who received treatment with neoadjuvant chemoIO.
Methods: The authors analyzed records of patients with stage IB-III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions.
Mammographic Calcifications Add Uncertainty in Predicting Response to Neoadjuvant Chemotherapy.
Radiology
September 2025
Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710.
Calcifications Affect Pathologic Complete Response and MRI Prediction after Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer.
Radiology
September 2025
Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea.
Background The optimal surgical management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer with calcifications remains controversial, particularly when pathologic complete response (pCR) is suspected. Purpose To identify factors associated with pCR after neoadjuvant chemotherapy in patients with HER2-positive breast cancer and assess whether calcifications affect the performance of radiologic complete response (rCR) at MRI for predicting pCR. Materials and Methods This retrospective study included patients with HER2-positive breast cancer who received neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab and underwent surgery between January 2021 and October 2023.
View Article and Find Full Text PDFTeleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group (COSS).
Cancer Med
September 2025
Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
Purpose: Teleangiectatic osteosarcoma is a histologic subtype of osteosarcoma that can mimic aneurysmal bone cysts and has so far been incompletely characterized.
Patients And Methods: We used the database of the Cooperative Osteosarcoma Study Group COSS (patient-registration 1980-2019) to better understand this rare histologic variant.
Results: 223 eligible patients were identified, 164 having reference pathology (median age 15.
A Novel Approach for Cisplatin-Resistant Esophageal Squamous Cell Carcinoma via Amino Acid Transporter LAT1 Inhibition.
Cancer Med
September 2025
Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Background: Esophageal squamous cell carcinoma (ESCC) represents an aggressive cancer type associated with poor prognosis, often treated with neoadjuvant chemotherapy (NAC) using cisplatin-based regimens. However, cisplatin resistance limits therapeutic efficacy, necessitating a deeper understanding of resistance mechanisms. L-type amino acid transporter 1 (LAT1) plays a crucial role in amino acid uptake and is linked to cancer cell survival through activation of the mammalian target of rapamycin (mTOR) pathway.
View Article and Find Full Text PDF